Master Psychosocial Aspects
for MCCQE Part 1

What the MCCQE Part 1 Tests in Psychosocial Aspects

The MCCQE Part 1 Psychosocial Aspects domain tests your ability to recognize and manage common psychiatric and psychosocial presentations in a Canadian primary care context. You must demonstrate knowledge of DSM-5 diagnostic criteria, first-line pharmacotherapy (e.g., SSRIs for depression, benzodiazepines for acute anxiety), and non-pharmacologic interventions (CBT, IPT). Key presentations include major depressive disorder, generalized anxiety disorder, panic disorder, substance use disorders (alcohol, opioids), adjustment disorder, and delirium. You must differentiate between unipolar and bipolar depression, know when to screen for suicide risk (e.g., using the Columbia-Suicide Severity Rating Scale), and understand legal aspects such as capacity assessment and involuntary admission criteria. Emphasis is on clinical decision-making: selecting appropriate screening tools (PHQ-9, GAD-7, AUDIT), interpreting results, and initiating evidence-based treatment plans in a biopsychosocial framework.

High-Yield Concepts

• Major Depressive Disorder (MDD) Diagnosis & Treatment: Requires ≥5 of 9 DSM-5 criteria (including depressed mood or anhedonia) for ≥2 weeks. First-line pharmacotherapy: SSRIs (e.g., escitalopram 10-20 mg/day) or SNRIs (e.g., venlafaxine 75-225 mg/day). Use PHQ-9 for severity monitoring; score ≥10 indicates moderate depression. Combine with CBT or IPT. For severe or psychotic features, consider ECT.
• Generalized Anxiety Disorder (GAD) & Panic Disorder: GAD: excessive worry ≥6 months with ≥3 associated symptoms (restlessness, fatigue, irritability, muscle tension, sleep disturbance). First-line: SSRIs/SNRIs (e.g., sertraline 50-200 mg/day) or CBT. Panic disorder: recurrent unexpected panic attacks with ≥1 month of worry about recurrence. Acute treatment: short-term benzodiazepines (e.g., lorazepam 0.5-1 mg PRN) plus SSRI for long-term control.
• Alcohol Use Disorder (AUD) Screening & Management: Screen with AUDIT-C (score ≥3 women, ≥4 men positive) or full AUDIT (≥8 indicates harmful use). DSM-5: ≥2 of 11 criteria in 12 months. Withdrawal: CIWA-Ar protocol; severe withdrawal requires benzodiazepine (e.g., diazepam 10-20 mg q1h PRN). First-line pharmacotherapy for relapse prevention: naltrexone 50 mg/day or acamprosate 666 mg TID. Refer to CBT and mutual-help groups.
• Suicide Risk Assessment: Ask directly about suicidal ideation, plan, intent, and means. Use Columbia-Suicide Severity Rating Scale (C-SSRS) for structured assessment. High-risk factors: previous attempt, male sex, older age, substance use, access to lethal means. Acute management: safety plan, remove means, consider psychiatric admission. In Canada, involuntary admission requires risk of serious harm per provincial Mental Health Act.
• Capacity Assessment & Consent: Use the four-component model: ability to understand relevant information, appreciate its significance, reason about options, and communicate a choice. Presume capacity unless proven otherwise. In emergent situations without capacity, treat under implied consent or substitute decision-maker. For psychiatric patients, capacity can be impaired by psychosis, severe depression, or delirium.
• Delirium vs Dementia Differentiation: Delirium: acute onset, fluctuating course, impaired attention, often due to medical cause (e.g., infection, electrolyte imbalance, medications). Use CAM (Confusion Assessment Method) for diagnosis. Dementia: gradual onset, chronic, primarily memory loss with intact attention early. Delirium is a medical emergency; treat underlying cause, avoid benzodiazepines (except alcohol withdrawal), use haloperidol 0.5-2 mg IM/IV PRN for agitation.
• Opioid Use Disorder (OUD) & Pain Management: Screen with CAGE-AID or DAST-10. DSM-5: ≥2 of 11 criteria. For OUD, first-line pharmacotherapy: buprenorphine/naloxone (Suboxone) or methadone. Initiate buprenorphine after ≥12-24 hours of withdrawal (COWS ≥8). Naloxone kit for overdose prevention. Chronic pain: avoid long-term opioids; use multimodal analgesia (NSAIDs, gabapentinoids, physiotherapy).
• Adjustment Disorder: Emotional or behavioral symptoms within 3 months of an identifiable stressor, not meeting criteria for another disorder. Treatment: supportive counseling, CBT, stress management. Usually self-limited (≤6 months). Differentiate from MDD by absence of full criteria and temporal link to stressor. No specific pharmacotherapy; treat comorbid anxiety or depression if present.

Common Traps in Psychosocial Aspects Questions

• Confusing adjustment disorder with MDD: adjustment disorder does not require five symptoms or two-week duration; it is a reaction to a stressor that resolves when the stressor is removed.
• Using benzodiazepines as first-line for GAD or chronic anxiety: they are second-line due to dependence risk; SSRIs/SNRIs are preferred.
• Assuming capacity is intact in all psychiatric patients: capacity is decision-specific; a patient with psychosis may still have capacity for some decisions.
• Forgetting to screen for bipolar disorder before starting an antidepressant: if unrecognized, antidepressants can trigger mania; screen with Mood Disorder Questionnaire (MDQ).
• Treating delirium with benzodiazepines as first-line: benzodiazepines worsen delirium except in alcohol withdrawal; use low-dose haloperidol or atypical antipsychotics for agitation.
• Equating suicide risk assessment with simply asking 'do you feel suicidal?': must assess intent, plan, means, and protective factors using a structured tool like C-SSRS.

How to Revise Psychosocial Aspects for the MCCQE Part 1

For Psychosocial Aspects on MCCQE Part 1, prioritize DSM-5 diagnostic criteria for MDD, GAD, panic disorder, and AUD, as well as first-line pharmacotherapy (SSRIs, SNRIs, naltrexone) and non-pharmacologic treatments (CBT, IPT). Questions often present a clinical vignette requiring you to choose the most appropriate next step: initiate medication, refer for therapy, or assess suicide risk. Practice applying screening tools (PHQ-9, GAD-7, AUDIT, C-SSRS) to case scenarios. Focus on clinical reasoning: differentiate between unipolar and bipolar depression, delirium vs dementia, and adjustment disorder vs MDD. Review Canadian guidelines for involuntary admission and capacity assessment. Do not memorize rare syndromes; instead, master common presentations and evidence-based management algorithms.

Practise it: MedLumen has 50 Psychosocial Aspects questions for the MCCQE Part 1, each with a full explanation and references.